Biotech | November 30, 2021
Thermo Fisher Scientific’s new CRISPR Genome editing protein
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
Cell sorting technology supports researchers advancing new therapies
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Subscribe To Our Newsletter & Stay Updated
